Not Your Grandfather’s Cytokine: Antibody Engineering After Gazyva
This article was originally published in Pharmaceutical Approvals Monthly
Roche lays out plans for building on its glyco-engineered antibodies to support and eventually activate T-cell responses, including an IL-2 variant immunocytokine.
You may also be interested in...
Pink Sheet infographic illustrates new drug approval trends and highlights from the past decade at the US FDA.
Highlights of year-end application submissions including candidates from AstraZeneca, BioMarin, Lilly, MorphoSys, and Seattle Genetics.
Cardiovascular outcome trials are driving development in blockbuster SGLT-2 inhibitor and GLP-1 agonist classes to look beyond HbA1c levels to focus on cardiovascular and renal protective effects.